Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pain Away is a topical analgesic brand developed and marketed by Wellnex Life, following its acquisition of the brand in 2023. The product line features formulations such as creams, gels, and sprays primarily containing *Arnica montana* extract, often in combination with other natural ingredients like rosemary oil and eucalyptus oil. The therapeutic effect is largely attributed to sesquiterpene lactones, specifically helenalin, which penetrates the skin to exert anti-inflammatory and analgesic actions. The primary mechanism involves the inhibition of the transcription factor NF-κB, which reduces the expression of pro-inflammatory genes and cytokines. It is indicated for the relief of muscular aches, pains, joint inflammation, and bruising associated with sports injuries or chronic conditions like arthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pain Away (Wellnex Life).